Preadmission GLP-1 receptor agonist use not linked with adverse ICU outcomes
There were no significant differences in mortality or length of stay between ICU patients with and without prior glucagon-like peptide-1 (GLP-1) receptor agonist use, according to a retrospective single-center study.
Prior glucagon-like peptide-1 (GLP-1) receptor agonist use was not associated with in-hospital mortality, hospital length of stay, or ICU length of stay among critically ill patients, a single-center study found.
Researchers used data from one U.S. hospital to create 452 matched pairs of ICU patients and compared outcomes by whether they had been prescribed GLP-1 receptor agonists before admission. In-hospital mortality was similar in GLP-1 receptor agonist patients and the comparison group (5.1% vs. 4.9%; odds ratio [OR], 1.05 [95% CI, 0.58 to 1.91]; P=0.88). Mean hospital length of stay (13.7 vs. 13.4 days; P=0.77) and ICU length of stay (5.9 vs. 5.4 days; P=0.33) were also similar in the respective groups.
Limitations include lack of data on the reason for ICU admission, severity of illness scores, and detailed medication histories. The study authors also could not distinguish between patients who underwent surgical procedures during hospitalization and those who did not.
The study was published by the Journal of Hospital Medicine on Nov. 24. and a full summary of it is available in ACP Hospitalist, a publication exclusive to ACP members. Single sign-on is required.